AR103442A1 - Anticuerpos y receptores de antígenos quiméricos específicos de ror1 - Google Patents
Anticuerpos y receptores de antígenos quiméricos específicos de ror1Info
- Publication number
- AR103442A1 AR103442A1 ARP160100120A ARP160100120A AR103442A1 AR 103442 A1 AR103442 A1 AR 103442A1 AR P160100120 A ARP160100120 A AR P160100120A AR P160100120 A ARP160100120 A AR P160100120A AR 103442 A1 AR103442 A1 AR 103442A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- seq
- antibody
- heavy chain
- fragment
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 title abstract 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 title abstract 2
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un anticuerpo o un fragmento de unión al antígeno del mismo, caracterizado porque dicho anticuerpo o un fragmento de unión al antígeno comprende una región variable (VH) de la cadena pesada que comprende: una región determinante de complementariedad de la cadena pesada 3 (CDR-H3) que comprende la secuencia de aminoácidos que se muestra en la SEQ ID Nº 22, 29, 35, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 ó 174; o una CDR-H3 contenida en la secuencia de la cadena pesada variable (VH) que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185,186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209. Reivindicación 10: El anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 9, caracterizado porque la región VH comprende: una región determinante de complementariedad de la cadena pesada 1 (CDR-H1) que comprende la secuencia de aminoácido que se muestra en la SEQ ID Nº 20, 27, 33, 155, 156, 157, 158, 159, 160, 161, 162 ó 163 y/o una CDR-H1 contenida en la secuencia VH que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178,179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209; y/o una región determinante de complementariedad de la cadena pesada 2 (CDR-H2) que comprende la secuencia de aminoácidos que se muestra en la SEQ ID Nº 21, 26, 28, 34, 164, 165, 166, 167, 168, 169, 170, 171, 172 ó 173 y/o una CDR-H2 contenida en la secuencia VH que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209. Reivindicación 91: Una proteína de la superficie celular de cadena simple, caracterizada porque comprende el anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 90. Reivindicación 99: Un receptor de antígeno quimérico (CAR) caracterizado porque comprende una porción extracelular que comprende el anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 97 y un dominio de señalización intracelular. Reivindicación 106: Un ácido nucleico, caracterizado porque codifica el anticuerpo o un fragmento del mismo de cualquiera de las reivindicaciones 1 - 97, el conjugado de la reivindicación 98 o el receptor de antígeno quimérico de cualquiera de las reivindicaciones 99 - 105. Reivindicación 110: La composición de la reivindicación 109, caracterizada porque además comprende un excipiente farmacéuticamente aceptable. Reivindicación 114: El método de cualquiera de las reivindicaciones 112 - 113, caracterizado porque la enfermedad o el trastorno es un cáncer que expresa ROR1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562104664P | 2015-01-16 | 2015-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103442A1 true AR103442A1 (es) | 2017-05-10 |
Family
ID=55272713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100120A AR103442A1 (es) | 2015-01-16 | 2016-01-18 | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160208018A1 (es) |
| EP (2) | EP3245231B1 (es) |
| JP (2) | JP6865688B2 (es) |
| KR (1) | KR20170128234A (es) |
| CN (1) | CN107428833B (es) |
| AR (1) | AR103442A1 (es) |
| AU (1) | AU2016206457B2 (es) |
| CA (1) | CA2973964A1 (es) |
| ES (1) | ES2818103T3 (es) |
| MX (2) | MX2017009254A (es) |
| NZ (1) | NZ733841A (es) |
| TW (2) | TW202126682A (es) |
| WO (1) | WO2016115559A1 (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2973964A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| SG10201914069SA (en) | 2015-05-18 | 2020-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102847350B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| SMT202400223T1 (it) | 2015-11-25 | 2024-07-09 | Ligachem Biosciences Inc | Coniugati comprendenti gruppi autoimmolativi e metodi correlati ad essi |
| JP7120765B2 (ja) | 2015-11-25 | 2022-08-17 | レゴケム バイオサイエンシズ， インク． | ペプチド基を含む複合体及びそれに関連する方法 |
| MX2018009011A (es) | 2016-02-02 | 2018-11-19 | Hutchinson Fred Cancer Res | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
| CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
| EP3848392A1 (en) | 2016-10-07 | 2021-07-14 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102771581B1 (ko) | 2017-03-14 | 2025-02-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | 극저온 보관 방법 |
| JP7664680B2 (ja) | 2017-03-29 | 2025-04-18 | リガケム バイオサイエンシズ， インク． | ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 |
| CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
| KR102913213B1 (ko) | 2017-06-23 | 2026-01-15 | 벨로스바이오 인코포레이티드 | Ror1 항체 면역접합체 |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| AU2018336791B2 (en) | 2017-09-19 | 2025-08-21 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor T cell therapy and uses thereof |
| WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| US20210145882A1 (en) * | 2018-04-13 | 2021-05-20 | Fred Hutchinson Cancer Research Center | Methods for adoptive cell therapy targeting ror1 |
| CN112292185B (zh) | 2018-04-17 | 2025-07-29 | 塞德斯医疗公司 | 抗cd27和抗pd-l1抗体及双特异性构建体 |
| EA202092202A1 (ru) * | 2018-04-18 | 2021-07-23 | Экселиксис, Инк. | Конструкции антител к ror |
| SG11202010443WA (en) | 2018-05-09 | 2020-11-27 | Legochem Biosciences Inc | Compositions and methods related to anti-cd19 antibody drug conjugates |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| AU2019301147A1 (en) | 2018-07-10 | 2021-01-21 | Precigen, Inc. | ROR-1 specific chimeric antigen receptors and uses thereof |
| WO2020061498A1 (en) * | 2018-09-20 | 2020-03-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
| US20200102370A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| MX2021009087A (es) * | 2019-01-29 | 2021-09-08 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1). |
| US20230312708A1 (en) * | 2019-03-26 | 2023-10-05 | The Regents Of The University Of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| CN114641307A (zh) * | 2019-08-19 | 2022-06-17 | 艾佩斯瑞生物制药公司 | 抗cd19抗体及其用途 |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| CN114929751B (zh) * | 2019-09-27 | 2024-11-05 | 南京艾美斐生物医药科技有限公司 | Ror1特异性嵌合抗原受体及其治疗应用 |
| US12497454B2 (en) * | 2020-02-07 | 2025-12-16 | VelosBio Inc. | Anti-ROR1 antibodies and compositions |
| WO2021183207A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER |
| BR112022018105A2 (pt) | 2020-03-10 | 2022-11-22 | Massachusetts Inst Technology | Métodos para gerar células nk tipo-memória modificadas e composições das mesmas |
| JP2023518849A (ja) | 2020-03-26 | 2023-05-08 | バンダービルト・ユニバーシティ | 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体 |
| WO2021195485A1 (en) * | 2020-03-27 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| JP2023523335A (ja) | 2020-04-27 | 2023-06-02 | ツイスト バイオサイエンス コーポレーション | コロナウイルス用の変異体核酸ライブラリー相互参照 |
| WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| AU2021270299A1 (en) * | 2020-05-12 | 2022-12-15 | Lyell Immunopharma, Inc. | Chimeric antigen receptor spacers |
| WO2022010847A1 (en) | 2020-07-07 | 2022-01-13 | Cancure, Llc | Mic antibodies and binding agents and methods of using the same |
| TWI818308B (zh) * | 2020-09-03 | 2023-10-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用 |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2023250402A2 (en) | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| CA3204322A1 (en) | 2020-12-18 | 2022-06-23 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| AU2021409801B2 (en) | 2020-12-21 | 2026-01-08 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| WO2022138758A1 (ja) * | 2020-12-25 | 2022-06-30 | デンカ株式会社 | 標的抗原の測定方法並びにそれに用いる不溶性粒子及び標的抗原測定用キット |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| KR20240018454A (ko) | 2021-05-06 | 2024-02-13 | 주노 테라퓨틱스 게엠베하 | T 세포의 자극 및 형질도입 방법 |
| EP4423145A1 (en) | 2021-10-28 | 2024-09-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| KR20240125944A (ko) * | 2021-12-28 | 2024-08-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-ror1 항체 및 항-ror1 항체 약물 접합체 및 이의 의약적 용도 |
| CN118574845A (zh) * | 2022-01-29 | 2024-08-30 | 杭州中美华东制药有限公司 | 一种靶向ror1的抗体或其抗原结合片段及其应用 |
| US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
| JP2025513801A (ja) | 2022-04-08 | 2025-04-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多部位受容体及びシグナル伝達複合体 |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| TW202409087A (zh) * | 2022-07-06 | 2024-03-01 | 中國商諾納生物（蘇州）有限公司 | 抗ror1抗體 |
| EP4562134A1 (en) | 2022-07-29 | 2025-06-04 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
| EP4613774A1 (en) * | 2022-11-03 | 2025-09-10 | Nanjing Probio Biotech Co., Ltd. | Single domain antibody targeting human ror1 |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| CN120882434A (zh) * | 2023-03-23 | 2025-10-31 | 江苏恒瑞医药股份有限公司 | 抗ror1抗体与pbd类化合物的偶联物、其制备方法及其应用 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| DE68919715T2 (de) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| ES2601882T5 (es) | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
| AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| KR20060088905A (ko) | 2000-06-16 | 2006-08-07 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2425862C (en) | 2000-11-07 | 2013-01-22 | City Of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20050232921A1 (en) | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| WO2003085093A2 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| DK2289936T3 (en) | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| CA2762955A1 (en) | 2003-10-16 | 2005-04-28 | Imclone Llc | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| US8268582B2 (en) | 2003-10-22 | 2012-09-18 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| PT2489364E (pt) | 2003-11-06 | 2015-04-16 | Seattle Genetics Inc | Compostos de monometilvalina conjugados com anticorpos |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| WO2005097184A2 (en) | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8727132B2 (en) | 2007-12-07 | 2014-05-20 | Miltenyi Biotec Gmbh | Sample processing system and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| AU2010238723A1 (en) * | 2009-04-23 | 2011-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
| EP3219731A1 (en) * | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013022968A1 (en) | 2011-08-09 | 2013-02-14 | Athera Biotechnologies Ab | Antibodies binding to phosphorylcholine (pc) and/or pc conjugates |
| MY173865A (en) | 2011-09-22 | 2020-02-25 | Amgen Inc | Cd27l antigen binding proteins |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| BR112014020499A2 (pt) | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, célula - t, vetor, e, população persistente de células - t |
| CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| ES2842102T3 (es) | 2012-08-20 | 2021-07-12 | Hutchinson Fred Cancer Res | Método y composiciones para inmunoterapia celular |
| KR102134088B1 (ko) * | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| NZ746914A (en) | 2012-10-02 | 2020-03-27 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
| WO2014164554A1 (en) | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| RU2733652C2 (ru) | 2013-10-31 | 2020-10-06 | Фред Хатчинсон Кэнсер Рисерч Сентер | МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ |
| ES2837856T3 (es) | 2013-12-20 | 2021-07-01 | Hutchinson Fred Cancer Res | Moléculas efectoras quiméricas etiquetadas y receptores de las mismas |
| CN106458154A (zh) | 2014-03-26 | 2017-02-22 | 麦格纳车镜美国有限公司 | 使用投射图标的车辆功能控制系统 |
| PH12016502010B1 (en) | 2014-04-10 | 2023-08-16 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Drug related transgene expression |
| AP2016009586A0 (en) | 2014-05-29 | 2016-11-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| EP3174557B1 (en) | 2014-07-29 | 2018-10-17 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| CN107106611B (zh) | 2014-10-27 | 2021-11-23 | 弗雷德哈钦森癌症研究中心 | 用于提高过继细胞免疫疗法效力的组合物和方法 |
| CA2973964A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| US20180147271A1 (en) | 2015-05-18 | 2018-05-31 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| SG11201803098VA (en) | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| MX2018009011A (es) | 2016-02-02 | 2018-11-19 | Hutchinson Fred Cancer Res | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
| CN107557337B (zh) | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| MX2021009087A (es) | 2019-01-29 | 2021-09-08 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1). |
-
2016
- 2016-01-18 CA CA2973964A patent/CA2973964A1/en active Pending
- 2016-01-18 EP EP16702306.8A patent/EP3245231B1/en active Active
- 2016-01-18 EP EP20178573.0A patent/EP3760644A1/en not_active Withdrawn
- 2016-01-18 AR ARP160100120A patent/AR103442A1/es unknown
- 2016-01-18 CN CN201680016204.1A patent/CN107428833B/zh not_active Expired - Fee Related
- 2016-01-18 AU AU2016206457A patent/AU2016206457B2/en not_active Ceased
- 2016-01-18 TW TW109132171A patent/TW202126682A/zh unknown
- 2016-01-18 ES ES16702306T patent/ES2818103T3/es active Active
- 2016-01-18 US US14/997,991 patent/US20160208018A1/en not_active Abandoned
- 2016-01-18 MX MX2017009254A patent/MX2017009254A/es unknown
- 2016-01-18 KR KR1020177022796A patent/KR20170128234A/ko not_active Abandoned
- 2016-01-18 JP JP2017537510A patent/JP6865688B2/ja active Active
- 2016-01-18 TW TW105101422A patent/TWI718118B/zh not_active IP Right Cessation
- 2016-01-18 WO PCT/US2016/013808 patent/WO2016115559A1/en not_active Ceased
- 2016-01-18 NZ NZ733841A patent/NZ733841A/en unknown
-
2017
- 2017-07-13 MX MX2021009151A patent/MX2021009151A/es unknown
-
2018
- 2018-06-04 US US15/997,635 patent/US10889652B2/en active Active
-
2020
- 2020-12-14 US US17/121,549 patent/US11919970B2/en active Active
-
2021
- 2021-01-15 JP JP2021004675A patent/JP2021061857A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107428833A (zh) | 2017-12-01 |
| EP3760644A1 (en) | 2021-01-06 |
| NZ733841A (en) | 2024-01-26 |
| MX2021009151A (es) | 2021-09-10 |
| TW202126682A (zh) | 2021-07-16 |
| AU2016206457A1 (en) | 2017-08-03 |
| EP3245231B1 (en) | 2020-08-12 |
| MX2017009254A (es) | 2017-10-12 |
| US20160208018A1 (en) | 2016-07-21 |
| WO2016115559A1 (en) | 2016-07-21 |
| JP2021061857A (ja) | 2021-04-22 |
| CA2973964A1 (en) | 2016-07-21 |
| US20210238309A1 (en) | 2021-08-05 |
| JP2018503380A (ja) | 2018-02-08 |
| KR20170128234A (ko) | 2017-11-22 |
| ES2818103T3 (es) | 2021-04-09 |
| JP6865688B2 (ja) | 2021-04-28 |
| AU2016206457B2 (en) | 2021-11-11 |
| TWI718118B (zh) | 2021-02-11 |
| US10889652B2 (en) | 2021-01-12 |
| TW201639880A (zh) | 2016-11-16 |
| US20180265593A1 (en) | 2018-09-20 |
| EP3245231A1 (en) | 2017-11-22 |
| US11919970B2 (en) | 2024-03-05 |
| CN107428833B (zh) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103442A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| EA201891066A1 (ru) | Антитела к ror1 | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| AR075849A1 (es) | Moleculas de anticuerpos que tienen especificidad de union por il-13 humana | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |